Physician profile
Bart Donald Beaver
NPI 1467468207
$6,880.23
in general payments reported to CMS, 2019-2025
27 companies · $1,802 in 2025
The $1,802 reported for 2025 was more than what 82% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $175 · 2021: $1,614 · 2022: $2,039 · 2023: $514 · 2024: $464 · 2025: $1,802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,751 · Travel and Lodging: $1,030.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,750.83 |
| Travel and Lodging | $1,029.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medwest Associates | $2,430.84 | 2021-2022 | |
| Treace Medical Concepts, INC. | $1,698.08 | 2021-2025 | |
| Smith+Nephew, INC. | $665.91 | 2019-2025 | Grafix Pl, Grafix |
| Organogenesis INC. | $629.85 | 2021-2023 | Puraply |
| Stryker Corporation | $340.14 | 2020-2025 | Limflow System, Augment Injectable, Actishield |
| Fusion Orthopedics USA, LLC | $208.43 | 2024 | |
| Abbott Laboratories | $194.69 | 2023-2024 | Proclaim, Eterna |
| Horizon Therapeutics Plc | $130.98 | 2019-2023 | Krystexxa |
| Biotissue Holdings INC. | $112.54 | 2022 | |
| Kerecis Limited | $68.27 | 2023-2025 | Kerecis Omega3 Surgiclose, Kerecis Surgiclose, Kerecis Omega3 Marigen |
| Paratek Pharmaceuticals, INC. | $55.34 | 2022-2024 | Nuzyra |
| Sandoz INC. | $54.75 | 2019 | |
| Integra Lifesciences Corporation | $29.88 | 2022 | |
| Bioventus LLC | $29.70 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $27.44 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $23.89 | 2025 | Flexitouch Plus, Nimbl |
| Triad Life Sciences INC. | $23.77 | 2022 | |
| Merck Sharp & Dohme LLC | $22.33 | 2019 | |
| Paragon 28, INC. | $19.16 | 2025 | Tenotac |
| Lightbody Medical Technologies INC | $17.05 | 2024 | |
| Curonix LLC | $16.05 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Medshape, INC. | $15.89 | 2023 | Dynanail Hybrid |
| Orthofix Medical, INC. | $15.86 | 2019 | |
| Melinta Therapeutics, LLC | $14.90 | 2021 | |
| Nabriva Therapeutics, Plc | $12.76 | 2022 | |
| Hikma Pharmaceuticals USA | $12.01 | 2020 | |
| Cardiovascular Systems INC. | $9.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bart Beaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.